购物车
  • 全部删除
  • TargetMol
    您的购物车当前为空

Tofacitinib

产品编号 T6321Cas号 477600-75-2
别名 托法替尼, Tasocitinib, CP-690550

Tofacitinib (Tasocitinib) 是一种 Janus 激酶抑制剂,抑制 JAK3/2/1 (IC50=1/20/112 nM),具有口服活性。Tofacitinib 被用于治疗中度至重度类风湿性关节炎。

Tofacitinib

Tofacitinib

纯度: 99.71%
产品编号 T6321 别名 托法替尼, Tasocitinib, CP-690550Cas号 477600-75-2

Tofacitinib (Tasocitinib) 是一种 Janus 激酶抑制剂,抑制 JAK3/2/1 (IC50=1/20/112 nM),具有口服活性。Tofacitinib 被用于治疗中度至重度类风湿性关节炎。

规格价格库存数量
5 mg¥ 297现货
10 mg¥ 483现货
25 mg¥ 813现货
50 mg¥ 1,230现货
100 mg¥ 1,980现货
200 mg¥ 2,890现货
500 mg¥ 4,900现货
大包装 & 定制
加入购物车
实验操作小课堂
查看更多

"Tofacitinib"的相关化合物库

选择批次:
纯度:99.71%
联系我们获取更多批次信息
TargetMol 的所有产品仅用作科学研究或药证申报,不能被用于人体,我们不向个人提供产品和服务。请您遵守承诺用途,不得违反法律法规规定用于任何其他用途。

产品介绍

生物活性
产品描述
Tofacitinib (Tasocitinib) is a Janus kinase inhibitor that inhibits JAK3/2/1 (IC50=1/20/112 nM) and is orally active. Tofacitinib is used for the treatment of moderate to severe rheumatoid arthritis.
靶点活性
JAK3:1 nM, JAK1:112 nM, JAK2:20 nM
体外活性
方法: 人类 MM 细胞系 MM.1S 与永生化 BMSC 系 HS5 和 HS27A 共培养,用 Tofacitinib (0-10 µM) 处理 24 h,通过 CellTiter-Glo reagent 检测细胞活力。
结果: 与单培养生长相比,MM.1S 细胞数量显著增加,证实了该细胞系中基质诱导的增殖信号。Tofacitinib 处理以剂量依赖的方式减少了 MM.1S 细胞数量。Tofacitinib 单独对 MM.1S 细胞存活率或单独对基质细胞没有影响。[1]
方法: NK-92 细胞用 Tofacitinib (50 nM) 处理过夜,再用 IL-15 (2.33 nM) 处理 2 h,检测 STAT1 磷酸化。
结果: Tofacitinib 阻断 NK-92 细胞中的 IL-15 信号传导。Tofacitinib 通过阻断 STAT 蛋白磷酸化来破坏 JAK/STAT 信号传导。[2]
体内活性
方法: 为检测体内抗肿瘤活性,用 Tofacitinib (21.5 mg/kg,50% DMSO+10% PEG 400+40% water) 皮下注射给携带原位扩散 MM.1S 异种移植物的 NSG 小鼠,每天一次,持续四周。
结果: 小鼠存活率显著提高,并且基于生物发光成像定量,肿瘤负荷显著降低。[1]
激酶实验
JAK3 Kinase Assay: A fragment encoding the catalytic domain of human JAK3 (785aa to 1125aa, JH1 catalytic domain) is amplified by PCR from the full length cDNA and cloned into the EcoRI site of the baculovirus transfer vector pVL1393. Recombinant baculovirus is used to infect Sf9 (Spodoptera frugipedra) cells and recombinant GSTJAK3 fusion protein is isolated on glutathione sepharose. The fusion protein is eluted with reduced glutathione and stored in buffer containing 50 mM Tris, pH 7.5, 10 mM DTT and 10% glycerol. JAK3 kinase activity is measured by ELISA as follows: Plates are coated overnight with a random L-glutamic acid and tyrosine co-polymer (4:1) (100 ug/mL). The plates are washed and recombinant JAK3 JH1:GST (100 ng/well) with or without inhibitors is incubated at room temperature for 30 minutes, after which HRP-conjugated PY20 anti-phosphotyrosine antibody (ICN) is added and developed by TMB (3,3',5,5'-tetramethylbenzidine). Other kinases (Table 1) are produced in E. coli or in insect cells, depending upon what is found to be optimal for the given kinase. The catalytic activity of tyrosine kinases is easured using the aftorementioned ELISA, whereas serine/threonine kinases are assayed using radioactive enzyme assays.
细胞实验
To measure IL-2-dependent proliferation, isolated lymphocytes are resuspended to a cell density of 1-2 × 106/mL in complete RPMI medium (RPMI 1640 containing 10% (w/v) fetal calf serum (FCS), 1%(w/v) penicillin and treptomycin).Phytohemagluttinin (PHA) is added to a final concentration of 10 mg/mL, and the culture incubated for 3 days at 37 °C in a humidified 5% (v/v) CO2 incubator to upregulate IL-2R and JAK3 expression. IL-2 (200U/mL), with or without CP-690,550 is then added and the cells are incubated for 72 hours at 37 °C in a humidified 5% (v/v) CO2 incubator, after which 50 mL of 3H-thymidine (5mCi/mL) is added. The plates are incubated for an additional 18 hours, harvested with a 96-well harvester, and counted on a scintillation counter. HUO3 cells are maintained in culture with granulocyte-macrophage colony stimulating factor and human foreskin fibroblasts are maintained in culture with 10% fetal calf serum. CP-690550 is added to freshly plated cells and cultured for 4 days. 3Hthymidine is added during the last 18 hours of the culture period. (Only for Reference)
别名托法替尼, Tasocitinib, CP-690550
化学信息
分子量312.37
分子式C16H20N6O
CAS No.477600-75-2
储存&溶解度
存储Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
溶解度信息
H2O: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 3.12 mg/mL (9.99 mM), Sonication is recommended
Ethanol: 0.76 mg/mL (2.43 mM), Sonication is recommended.
溶液配制表
Ethanol/DMSO
1mg5mg10mg50mg
1 mM3.2013 mL16.0067 mL32.0133 mL160.0666 mL
DMSO
1mg5mg10mg50mg
5 mM0.6403 mL3.2013 mL6.4027 mL32.0133 mL

计算器

  • 摩尔浓度 计算器
  • 稀释 计算器
  • 配液 计算器
  • 分子量 计算器

体内实验配液计算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:
TargetMol | Animal experiments比如您的给药剂量是 10 mg/kg ,每只动物体重 20 g ,给药体积 100 μLTargetMol | Animal experiments 一共给药动物 10 只 ,您使用的配方为 5% TargetMol | reagent DMSO+ 30%PEG300+ 5%Tween 80 + 60% ddH2O. 那么您的工作液浓度为 2 mg/mL
母液配置方法: 2 mg 药物溶于 50 μLDMSOTargetMol | reagent ( 母液浓度为 40 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:50μLDMSOTargetMol | reagent 母液,添加 300 μLPEG300TargetMol | reagent 混匀澄清,再加 50μLTween 80, 混匀澄清,再加 600μLddH2OTargetMol | reagent 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

1 请输入动物实验的基本信息
mg/kg
g
μL
2 请输入动物体内配方组成,不同的产品配方组成不同,如有配方需求,可先联系我们提供正确的体内配方。
% DMSO
%
%Tween 80
%ddH2O

剂量转换

对于不同动物的给药剂量换算,您也可以参考 更多

关键词

Related Tags: buy Tofacitinib | purchase Tofacitinib | Tofacitinib cost | order Tofacitinib | Tofacitinib chemical structure | Tofacitinib in vivo | Tofacitinib in vitro | Tofacitinib formula | Tofacitinib molecular weight